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Background: To compare highly sophisticated intensity-modulated radiotherapy (IMRT) delivered by either helical
tomotherapy (HT), RapidArc (RA), IMRT with protons (IMPT) in patients with locally advanced cervical cancer.
Methods and materials: Twenty cervical cancer patients were irradiated using either conventional IMRT, VMAT or
HT; ten received pelvic (PEL) and ten extended field irradiation (EFRT). The dose to the planning-target volume A
(PTV_A: cervix, uterus, pelvic ± para-aortic lymph nodes) was 1.8/50.4 Gy. The SIB dose for the parametrium (PTV_B),
was 2.12/59.36 Gy. MRI-guided brachytherapy was administered with 5 fractions up to 25 Gy. For EBRT, the lower
target constraints were 95% of the prescribed dose in 95% of the target volume. The irradiated small bowel (SB)
volumes were kept as low as possible. For every patient, target parameters as well as doses to the organs at risk
(SB, bladder, rectum) were evaluated intra-individually for IMRT, HT, VMAT and IMPT.
Results: All techniques provided excellent target volume coverage, homogeneity, conformity. With IMPT, there was
a significant reduction of the mean dose (Dmean) of the SB from 30.2 ± 4.0 Gy (IMRT); 27.6 ± 5.6 Gy (HT); 34.1 ± 7.0
(RA) to 18.6 ± 5.9 Gy (IMPT) for pelvic radiation and 26.3 ± 3.2 Gy (IMRT); 24.0 ± 4.1 (HT); 25.3 ± 3.7 (RA) to 13.8 ± 2.8
Gy (IMPT) for patients with EFRT, which corresponds to a reduction of 38-52% for the Dmean (SB). Futhermore, the
low dose bath (V10Gy) to the small bowel was reduced by 50% with IMPT in comparison to all photon techniques.
Furthermore, Dmean to the bladder and rectum was decresed by 7-9 Gy with IMPT in patents with pelvic radiation
and EFRT.
Conclusion: All modern techniques (were proved to be dosimetrically adequate regarding coverage, conformity
and homogeneity of the target. Protons offered the best sparing of small bowel and rectum and therefore could
contribute to a significant reduction of acute and late toxicity in cervical cancer treatment.
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Histology: Squamous cell: 16
Adenocarcinoma: 3
Adeno-squamous: 1
Treatment volume Pelvis only (PEL): 10
Extended field (EFRT): 10
Pelvic lymph nodes pN0: 4
pN1: 11
pNx: 5
Para-aortic lymph nodes pM0: 7
pM1: 8*
pMX: 5**
*All patients underwent extended field radiotherapy; **2/5 pMX patients
underwent extended field radiotherapy because of enlarged nodes.
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Concomitant cisplatin-based chemo-radiation in the
treatment of locally advanced (uterine) cervical cancer is
the standard of care but leads to considerable acute and
late toxicity affecting the gastrointestinal (GI) and geni-
tourinary (GU) tracts [1-4]. In patients with para-aortic
disease, the use of extended field radiation therapy (EFRT)
can be associated with an high incidence of acute and late
GI toxicity [5-8].
Intensity-modulated radiotherapy (IMRT) significantly
reduces acute and late toxicity to the organs at risk
(OAR) [9-11]. A growing body of evidence indicates a
strong dose-volume relationship for the development of
bowel toxicity. Quantec recommended to allow V15Gy =
120 cc if individual bowel loops are outlined or V45Gy ≤
195 cc if entire peritoneal potential space of bowel is
outlined [12]. Using the constraints of <40% of the bowel
should receive at least 35 Gy and <50% of the rectum re-
ceiving at least 45 Gy, only 1 out of 54 patients developed
grade 3 GI toxicity during an adjuvant chemoradiation
trial in cervical cancer [13]. Isohashi et al. [14] demon-
strated that the volume of small bowel receiving more
than 40 Gy resulted a clear independent predictor of
chronic GI complication. Chopra et al. in a prospective
study on 71 patients demonstrated the relevance (in
multivariate analysis) of the volume of small and large
bowels receinving more than 15 Gy. Also the volumes of
small bowel receiving 30 and 40 Gy resulted significant in
univariate analysis [15].
With its characteristic Bragg peak, proton therapy
holds the promise of further reduction of toxicity to or-
gans at risk [16-20]. Different techniques like Intensity
Modulated Proton Therapy (IMPT) and passive scat-
tered proton therapy are available. IMPT is progressively
being adopted as a standard for proton therapy although
the experience with large treatment volumes is still rela-
tively limited.
Intensity modulated protons, with the scanning beam
technology, are able to modulate intensities to fulfill
dose constraints to the target and the organs at risk.
Data from a small study on only five patients with cer-
vical carcinoma suggested a significant decrease of the
doses to the kidneys and the femoral heads with protons.
Sparing of rectal wall and bladder was superior with pro-
tons as well [21]. Another study on ten patients, mainly
in the adjuvant situation after surgery, has shown that
compared with IMRT alone, the combination of passive
scattering protons or intensity modulated protons lead
to a statistically significant decrease of dose to the or-
gans at risk, most notably the small and large bowel and
kidney, in addition to the bowel and body dose, all while
maintaining excellent target coverage [22].
With regard to target parameters all plans were com-
parable. Dose volume parameters for the bowels weresignificantly improved with protons compared to inten-
sity modulated photons, with mean dose reductions of
50–80%. The study was limited by the number of pa-
tients and the use of outdated 3D-radiation which was
compared with the advanced techniques [21]. Only one
publication focused on oncologic outcome of brachy-
therapy emulation with protons and toxicity [23].
Our objective in the present study was to assess whether
intensity modulated protons provides any benefit in an
intra-individual comparison to all available sophisticated
photon techniques with regard to the target and organs at
risk for cervical cancer patients undergoing pelvic irra-
diation or extended field irradiation for locally advanced
cervical cancer. The planning goal was to maintain high
target coverage while keeping the dose to the bowel as
low as possible.
Materials and methods
Patient characteristics and treatment planning
Patients’characteristics are shown in Table 1. All patients
where treated according to Helsinki declaration; for the
present study, being a planning experiment in-silico
without actual treatment, data derived from previous
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ethical committee approval was needed. All patients re-
ceived a planning CT scan (CT scanner LightSpeed, GE
Healthcare) with intravenous contrast media at a slice
thickness of 3.75 mm. In case of para-aortic involve-
ment, the CT scans were done from the diaphragm to
the trochanter minor. In all other patients, the CT scan
was performed from the 2nd lumbar vertebra to the tro-
chanter minor. The planning CT was performed while
the patient was in the supine position using a knee and
foot positioning device, and patients were asked to have
a full bladder.
Target volumes and OAR were delineated in all axial CT
slices according to the recommendations [24,25]. The plan-
ning target volumes were divided into PTV-A and PTV-B
(boost) volumes, and the concept of simultaneously-
integrated boost (SIB) was applied. The clinical target
volume (CTV-A) was defined as the macroscopic
tumour, including the cervix and the corpus uteri and
external, internal, common iliac, and pre-sacral LNs
plus/minus the paraaortic LNs with a 5-mm margin.
The volume (PTV-A) was outlined as the CTV-A with a
1-cm margin in all directions (inclusive of set-up and
motion related margins, not distinguished between the
two as per institutional protocol). In patients with nega-
tive para-aortic lymphnodes, the upper field border was
at the level of the L4/5 interspace (the pelvis only group,
PEL). In patients with para-aortic lymphnode metasta-
ses, the para-aortic region was included in the CTV-A
up to the level of the renal vessels (the extended field
radiotherapy group, EFRT). The caudal PTV slice was at
the level of the obturator foramen.
For the SIB target volume defined as CTV-B, the high-
risk volume (parametria and surrounding lymphatic
tissue) was delineated by titanium clips that were posi-
tioned during laparoscopic staging. In patients who did
not undergo laparoscopic staging, standardized borders
for boost definition were as follows: for the cranial
border, the bifurcation of the common iliac artery; for
the lateral border, the iliopsoas muscle; for the medial
border, the lateral part of the uterus; and for the caudal
border, the pubo-coccygeal muscle as part of the levator
ani. For the SIB target volume PTV-B, one cm was
added to the CTV-B.
The following OARs were delineated: spinal cord, fem-
oral heads, kidneys, bladder, rectum up to the sigmoidal
loop, and the bowels as a whole peritoneal cavity except
for the lymph nodes, the muscles and the OARs other
than the bowels. The delineation of the bowels exceeded
the upper border of the PTV-A by 2 slices.
In addition to external beam radiotherapy, these pa-
tients underwent Ir-192-HDR-brachytherapy with a total
dose of 25 Gy (5 fractions at 5 Gy each) delivered to
macroscopic tumour defined on the basis of the MRIimage (Gammamed 12i and Brachyvision, Varian Medical
Systems, Palo Alto, CA), which was not included in the
analysis.Dose prescription, planning parameters, and radiation
technique
According to the SIB technique, the PTV-A is the differ-
ence between the previously assigned PTV-A and PTV-B
(SIB target volume). PTV-B is consistent for pelvic and
EFRT patients. All dose prescriptions and constraints for
the PTV-A, as well as the following analysis, refer to this
volume difference unless otherwise noted.
The total dose prescribed for the PTV-A was 50.4 Gy
delivered in 28 fractions of 1.8 Gy. The corresponding
dose prescribed to the PTV-B was 59.36 Gy delivered in
28 fractions of 2.12 Gy. The lower constraint for both
types of PTV was 95% of the prescribed dose in 95% of
the target volume, and the upper dose constraint was
107%, which was only reasonable for PTV-B. The
bowels volumes receiving 45 Gy (V45Gy) and mean
dose to the small bowel were to be kept as low as
possible without compromising the PTV constraints.
Therefore, additional help structures in the form of PTV-
free bowels and a 1.5 cm shell were used. Other OAR
were also constrained so as not to exceed their critical
dose values, but they were considered less important than
the bowels.
All plans were optimised by experienced staff members,
one per each technique and blindly to each other. This
was to ensure homogeneity of quality within a technique,
best expertise between techniques and avoid subjective
biases as much as possible.Helical tomotherapy planning
Contouring for both IMRT modalities was performed
with the Treatment Planning System (TPS) of Eclipse
(Varian Medical Systems, Palo Alto, CA). The CT data-
sets with contoured structures were then transferred to
the Tomotherapy TPS (TomoTherapy Inc., Madison, WI),
enabling inverse treatment planning for photon irradiation
at 6MV with HT. Parameters for beamlet calculation were
a field width of 5 cm, pitch of 0.25, and normal resolution
mode. The maximum modulation factor we allowed for
the optimization was 2.5.Conventional linac-based IMRT planning
Conventional linac-based IMRT plans were calculated
for photon irradiation at 20MV using the Eclipse TPS.
Also, the TPS enables inverse planning. These plans
were generated for an arrangement of seven beams with
gantry angles of 45, 90, 115, 180, 245, 280, and 320°. The
dynamic (sliding window) technique was used.
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RapidArc (RA) plans were optimised with the Progres-
sive Resolution Optimisation algorithm in the Eclipse
TPS. The optimisation process is based on an iterative
inverse calculation that optimizes simultaneously the in-
stantaneous multi-leaf collimator (MLC) positions, the
dose rate, and the gantry rotation speed in order to
achieve the desired therapeutic dose distribution. Plans
were optimised for three full arcs. All dose calculations
for IMRT and RA plans were performed with the Anyso-
tropic Analytical Algorithm with a spatial resoluton of
2.5 mm.
IMPT planning
IMPT plans have been computed on the Eclipse TPS
(v.13) simulating a Varian ProBeam system. A nonlinear
universal Proton Optimizer was used for the scope.
For the final dose calculation, the Proton Convolution
Superposition algorithm was used. A constant RBE of
1.1 was applied. Accuracy of the calculation is discussed
for example in [26,27], pointing to a difference between
calculated and measured point dose for prostate treatment
of 0.0 ± 0.7% and a γ-index of 96.2 ± 2.6%.
The Bragg peak distribution in depth was derived from
a range of energies from 70 to 245 MeV. Energy layers
were determined to cover proximally and distally the tar-
get. Spot spacing was set to 4 mm, circular lateral target
margins were set to 5 mm, proximal and distal margins
to 5 mm.
For each patient, in the PEL group without inclusion
of the pelvic nodes, three beams were used to optimize
the plans: two oblique-anterior (OA) fields and one pos-
terior. Gantry angles of the two OA fields were individu-
ally chosen to identify the best geometrical setting
individually with the aim of minimising the involvement
of the bowels. For the patients in the EFRT group, those
including the pelvic nodes, two additional anterior-
posterior fields were used to cover the more cranial sec-
tion of the target volumes.
Dose volume histogram (DVH) analysis
The DVH analysis was applied to both the PTVs and the
OARs, respectively. The PTVs were analyzed with regard
to dose conformity and homogeneity [28]. One of com-
ponents for conformity evaluation is the coverage of
corresponding target volumes by the prescribed dose,
whereas for the SIB target volume PTV-B, the target def-
inition is unambiguous. The main PTV target volume
should be the sum of PTV-A and PTV-B, but only
throughout the conformity analysis. The Conformity Index
(CI) was calculated as the ratio of the volume receiving
95% of the prescribed dose (V95%) and the corresponding
PTV. The CI definition is useful but fails in cases of insuf-
ficient coverage. Therefore, we used the ConformityNumber (CN) as an additional conformity criterion, which
is a product of the coverage factor (CVF) and the healthy
tissue conformity index (HTCI): CN =CVFxHTCI. The
CVF is defined as the ratio of the part of the PTV receiv-
ing 95% of prescribed dose and the whole PTV. The HTCI
is defined as a ratio of two volume parts, the PTV and the
total volume, receiving at least 95% of the prescribed dose.
Homogeneity (HI) was defined as the ratio of the dose re-
ceived by 95% (D95%) of the volume to the minimum dose
received by the “hottest” 5% (D5%) of the target volume of
interest [29]. The range of ±5% was chosen as a com-
promise between the ranges of ±10% and ±2% recom-
mended for total body and head and neck irradiation,
respectively. Most of the OAR were analyzed by mean
dose (Dmean) or doses to 10% and 90% of the organ
volume, respectively (D10%, D90%).
Statistics
Results were analyzed to assess the benefit for each
treatment group separately. Data from all plans were
compared with the non-parametric Wilcoxon exact
signed rank test (SPSS 15.0, Inc., Chicago, IL). Statistical
significance was assumed at the level of p ≤ 0.05.
Results
Twenty patients with FIGO stage IB2-IVA with a mean
age of 46 years (33–71 years) were treated with primary
chemo-radiation. Ten patients underwent pelvic irradi-
ation, only, and ten patients underwent EFRT. All under-
went external beam radiotherapy and brachytherapy
and received simultaneous chemotherapy with cisplatin
40 mg/m2 of the body surface area weekly concomitant
with radiation therapy. Patients’characteristics and lymph
node stage is shown in Table 1.
The mean volume values for PTV-A were 1297.5 ±
211.8 cc for PEL and 1539.8 ± 334.1 cc for EFRT. The
corresponding volume values for the sum of PTV-A and
PTVB in the PEL and EFRT groups were 1651.0 ±
290.4 cc and 1835.9 ± 396.8 cc, respectively. Mean vol-
ume values for PTV-B did not differ with 353.5 ± 99.4 cc
(PEL) and 334.0 ± 130.6 cc (EFRT). The mean volume
values for the SB were more than doubled for EFRT with
3283.3 ± 992.8 cc. The median bladder and rectal volume
was 212 and 69.2 cc, respectively.
Comparison of HT , IMPT, IMRT and VMAT
All techniques fulfilled the defined the constraint for the
PTVs D95% > 95%. Detailed results are shown in Table 2.
Although, differences were small, the best homogeneity
for the PTV-A could be achieved with HT and IMRT for
PEL and IMRT and VMAT for EFRT. Concerning PTV-B,
IMPT created most homogeneous plans, followed by HT
for PEL and IMRT for EFRT (as and example see Figure 1
Table 2 Summary of DVH analysis
Volume Pelvic RT EFRT
HT IMPT IMRT VMAT HT IMPT IMRT VMAT
OAR Parameters
Bowel V10Gy (%) 99.1 ± 1.3
a,b,c 52.4 ± 15.8d,e 93.7 ± 4.1 94.6 ± 2.8 96.5 ± 4.3a 40.3 ± 7.1d,e 90.9 ± 6.6 94.0 ± 5.8
Bowel V20Gy (%) 74.8 ± 12.6
a,c 37.7 ± 13.3d,e 73.7 ± 12.0 74.2 ± 3.1 61.9 ± 1.4a,c 28.2 ± 7.0d,e 60.6 ± 9.3 59.8 ± 8.5
Bowel V30Gy (%) 47.1 ± 18.8
a,c 28.4 ± 10.6d,e 45.6 ± 12.9 44.8 ± 10.8 36.0 ± 10.6a,c 18.2 ± 5.5d,e 34.2 ± 8.5 32.7 ± 9.3
Bowel V50Gy (%) 6.7 ± 3.6 5.6 ± 2.1
d,e 11.8 ± 4.5 8.9 ± 2.5 6.5 ± 3.3a 2.9 ± 0.9d,e 8.8 ± 2.5 8.0 ± 2.8
Bowel Dmean (Gy) 27.6 ± 5.6
a 18.6 ± 5.9d,e 30.2 ± 4.0 34.1 ± 7.0 24.0 ± 4.1a 13.8 ± 2.8d,e 26.3 ± 3.2 25.3 ± 3.7
Rectum Dmean (Gy) 47.8 ± 3.6
a 41.4 ± 5.3e 47.2 ± 4.8 48.3 ± 1.6 48.2 ± 2.4a 41.3 ± 3.0d,e 48.5 ± 3.2 48.3 ± 1.5
Bladder Dmean (Gy) 49.2 ± 1.4
a 41.6 ± 5.8d,e 49.1 ± 3.4 50.1 ± 1.6 48.4 ± 2.8a 40.8 ± 6.4d,e 49.5 ± 3.8 48.9 ± 2.3
PTV Parameters
HI PTV_A 0.88 ± 0.02 0.87 ± 0.01 0.88 ± 0.01 0.87 ± 0.01 0.87 ± 0.01 0.87 ± 0.01 0.88 ± 0.01 0.88 ± 0.01
HI PTV_B 0.94 ± 0.01a,b 0.96 ± 0.01d,e 0.92 ± 0.01f 0.94 ± 0.01 0.94 ± 0.02a 0.96 ± 0.01d,e 0.93 ± 0.01 0.94 ± 0.01
CN PTV_A 0.88 ± 0.03a,b 0.92 ± 0.01d,e 0.82 ± 0.02f 0.88 ± 0.03 0.85 ± 0.13 0.88 ± 0.01d 0.82 ± 0.06 0.88 ± 0.03
CN PTV_B 0.87 ± 0.02 0.88 ± 0.05 0.84 ± 0.06 0.88 ± 0.03 0.86 ± 0.06a,c 0.89 ± 0.03d 0.78 ± 0.08 0.87 ± 0.08
CI PTV_A 1.09 ± 0.05a,b,c 1.03 ± 0.02d,e 1.20 ± 0.03f 0.98 ± 0.01 1.16 ± 0.07 1.05 ± 0.02d,e 1.22 ± 0.11f 0.97 ± 0.01
CI PTV_B 1.07 ± 0.06 1.08 ± 0.07 1.16 ± 0.09f 1.09 ± 0.05 1.15 ± 0.11 1.07 ± 0.06d 1.24 ± 0.13f 1.08 ± 0.10
HI: homogeneity index; CN: conformality number; CI: conformality index. VxGy: volume receiving at least x Gy. HT: helical tomotherapy; IMPT: intensity modulated
proton therapy; IMRT: intensity modulated radiation therapy; VMAT: volumetric modulated arc therapy. EFRT: extended field radiation therapy. Statistical
significance when p < 0.05. aHT vs IMPT; bHT vs IMRT; cHT vs VMAT; dIMPT vs IMRT; eIMPT vs VMAT; fIMRT vs VMAT.
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qualitative results were obtained for the other techniques).
With IMPT, there was a significant reduction of the
mean dose (Dmean) of the bowels from 30.2 ± 4.0 Gy
(IMRT); 27.6 ± 5.6 Gy (HT); 34.1 ± 7.0 (VMAT) to 18.6 ±
5.9 Gy (IMPT) for pelvic radiation and 26.3 ± 3.2 GyFigure 1 Example of Conformity and homogeneity of IMRT versus IMPT. B
Yellow = 95% isodose of PTV_B with 59.36 Gy prescribed dose, Margenta: b(IMRT); 24.0 ± 4.1 (HT); 25.3 ± 3.7 (VMAT) to 13.8 ±
2.8 Gy (IMPT) for patients with EFRT, which corre-
sponds to a reduction of 38-52% for the Dmean (bowels),
(examples are shown in Figures 2 and 3). Futhermore,
the low dose bath (V10Gy) to the bowels was reduced by
50% with IMPT in comparison to all photon techniques.lue isodose = 95% isodose of PTV_A with 50.4 Gy prescribed dose;
owel contour.
Figure 2 Example of Volume covered by 20 Gy (V20Gy, blue) for a patient with EFRT, HT vs IMPT.
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techniques allowed to maintain the high dose irradiation
of the bowels to acceptable levels. The maximum bowel
involvement at 50 Gy was less than 190 cc (96% con-
fidence level) for IMRT and much less for all otherFigure 3 Examples of rectum and bowel sparing potential between techniqutechnques in the PEL group. In the EFRT group, this
ranged from about 400 cc for IMRT and VMAT to 150 cc
for IMPT with averages ranging from 280 cc to 90 cc.
Furthermore, Dmean to the bladder and rectum was
decresed by 7-9 Gy with IMPT in patents with pelvices. A and B: rectum, colorwash is at 45 Gy; B: SB, colowash is at 30 Gy.
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of the bowels could be reduced by IMPT, more pro-
nounced for the EFRT than for PEL (Table 2, Figure 2).
The dose to the kidneys is not reported in detail since,
for all optimisation engines, it was possible to achieve
for all patients, organ sparing well below the assumed
tolerance level of 30% for V15Gy also in the more chal-
langing case of the patients with EFRT.
Discussion
Proton beam therapy has been used for various indica-
tions. Its physical characteristic Bragg peak allows for
reducing the integral radiation dose to the normal tissue
and selective sparing of certain organs of risk while pro-
viding an equal or superior target coverage. Further-
more, proton radiotherapy has the potential to permit
dose escalation [17-20,30]. Few data is available with re-
gard to cervical cancer treatment with different indica-
tions, concepts and proton techniques [14,21-23].
In contrast, our aim was to keep the small bowel dose
as low as possible and we did not optimize plans in
order to decrease the bone marrow dose. Since intracavi-
tary brachytherapy delivered in conjunction with external
beam radiotherapy has been an important component of
the treatment of gynecologic cancers, GI toxicity is a
major concern. The significant reduction of the normal
tissue dose might result into a reduced risk of secondary
malignancies in these younger patients [22,31].
Our aim was to compare all available highly sophisti-
cated photon techniques like IMRT, helical tomotherapy
or volumetric modulated arc therapy with intensity modu-
lated protons in patients with pelvic and/or extended field
treatments for cervical cancer.
Milby [22] published a dosimetric comparison of
intensity-modulated radiotherapy with photons, only to
the pelvic lymph nodes in combination with either passive
scattering proton therapy IMPT or modulated photons to
the para-aortic nodal region in women with locally ad-
vanced gynecologic malignancies. Georg [21] evaluated in
a group of five patients with EFRT all these techniques.
According to our results, proton and photon techniques
were comparable in terms of homogeneity, conformity
and coverage. Small, non-significant differences were seen
with regard to homogeneity, conformation number and
conformity index in favor for intensity modulated protons
in our patients for pelvic radiation and extended field
radiation.
The most striking difference between proton and pho-
ton techniques was related to the organs at risk. Since
we have focused on further reduction of the considerable
gastro intestinal toxicity our goal was to decrease the
mean dose and the high dose volume as much as pos-
sible. Proton therapy resulted into a significant reduction
of either mean dose by 33%, 38% and 45% comparedwith tomotherapy, modulated photons and volumetric
modulated arc therapy respectively. One can assume
that such a reduction of Dmean to the small bowel leads
to a decrease in therapy related toxicity. In accordance
to our data, Milby [22] found that all plans maintained
excellent coverage of the planning target volume while
decreasing the V20Gy, V30Gy, V35Gy, and V40Gy of the
small bowel. The volume covered by 50 Gy was reduced
with protons in our patients and the low dose bath to
the bowels (V10%) could be nearly halved with protons,
both more pronounced for EFRT than for pelvic radi-
ation. The rectal Dmean could be reduced by 7-9 Gy.
Georg [21] reported on comparable rectal (wall) doses,
while Milby [22] did not emphasize this. Relating to the
therapeutic concept of external beam radiotherapy and
brachytherapy in the treatment of cervical cancer the
further dose reduction to the rectum is desirable and
contributes to less rectal toxicity [32]. Although bladder
dose was not a focus of this study, intensity modulated
protons reduced the Dmean to the bladder by 7-9 Gy.
The impact on toxicity is not clear, because no clear
dose response has been defined until now. Renal toxicity,
per se a factor of potential concern, was not identified as
a relevant issue in this study since, also for the patients
where the extension of the fields might involve these or-
gans, sufficient protection was obtained by all the
optimization engines. The quantitative tolerance consid-
ered for the study was V15Gy < 30% which is more re-
strictive than what derived from the QUANTEC data
[33] where this could be interpolated as V15Gy < 40%.
One limitation of the present study is linked to the use
of IMPT in the pelvis. Proton based intensity modula-
tion with scanned beam technology can be affected by
relevant range uncertainties (the uncertainty in the dose
deposition with depth) because of the presence of bowel
gas and/or bowel peristalsis. For these reasons, the clin-
ical use of IMPT in the pelvis cannot be considered fully
consolidated and detailed analysis of the impact of these
dose uncertainties should be further explored. More in
general, the use of IMPT with the inherent sharp dose
fall-off, dosimetrically advantageous, shall be carefully
considered and weighted against some obvious trade-
offs (motion management, range uncertainty, delivery
time, imaging and others). The IMPT are not necessarily
to be considered the ultimate perfect technique to use
but could be beneficial in some well selected challenging
conditions. The present study constitute a theoretical
investigation at planning level that might lead to deeper
pre-clinical studies.
Conclusion
Intensity modulated radiotherapy with photons, volu-
metric modulated arc therapy, helical tomotherapy and
intensity modulated proton techniques were compared
Marnitz et al. Radiation Oncology  (2015) 10:91 Page 8 of 9in cervical cancer patients. All techniques were proved
to be dosimetrically adequate with regard to coverage,
conformity and homogeneity. Intensity modulated pro-
tons offered the best sparing of the bowels and rectum
and there for could contribute to a significant reduction
of acute and late toxicity which should be proven in
clinical trials.
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